JP2014510518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510518A5 JP2014510518A5 JP2013553420A JP2013553420A JP2014510518A5 JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5 JP 2013553420 A JP2013553420 A JP 2013553420A JP 2013553420 A JP2013553420 A JP 2013553420A JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hsa
- substitution
- amino acid
- fcrn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 229920001184 polypeptide Polymers 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 102000008100 Human Serum Albumin Human genes 0.000 claims 25
- 108091006905 Human Serum Albumin Proteins 0.000 claims 25
- 238000006467 substitution reaction Methods 0.000 claims 19
- 235000018102 proteins Nutrition 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 12
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 11
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 230000005714 functional activity Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/024855 WO2011103076A1 (en) | 2010-02-16 | 2011-02-15 | Hsa-related compositions and methods of use |
| USPCT/US2011/024855 | 2011-02-15 | ||
| PCT/US2011/047040 WO2012112188A1 (en) | 2011-02-15 | 2011-08-09 | Hsa-related compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510518A JP2014510518A (ja) | 2014-05-01 |
| JP2014510518A5 true JP2014510518A5 (enExample) | 2014-09-04 |
Family
ID=46675795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553420A Pending JP2014510518A (ja) | 2011-02-15 | 2011-08-09 | Ｈｓａ関連組成物および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2675471A4 (enExample) |
| JP (1) | JP2014510518A (enExample) |
| KR (1) | KR20140012094A (enExample) |
| CN (1) | CN103379915A (enExample) |
| AU (1) | AU2011359378A1 (enExample) |
| CA (1) | CA2826683A1 (enExample) |
| WO (1) | WO2012112188A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| CA2789337A1 (en) * | 2010-02-16 | 2011-08-25 | Medimmune, Llc | Hsa-related compositions and methods of use |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| BR112013031943B1 (pt) | 2011-06-13 | 2021-10-13 | Csl Limited | Composição que compreende proteínas e anticorpos contra g-csfr |
| EP2780364A2 (en) * | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| KR20150118123A (ko) | 2013-02-16 | 2015-10-21 | 노보자임스 바이오파마 디케이 에이/에스 | 약동학적 동물 모델 |
| KR102191654B1 (ko) * | 2013-03-15 | 2020-12-16 | 애피바디 에이비 | 신규 폴리펩티드 |
| WO2014198834A1 (en) * | 2013-06-12 | 2014-12-18 | Pharis Biotec Gmbh | Peptides with antagonistic activities against natural cxcr4 |
| US20160222087A1 (en) * | 2013-09-13 | 2016-08-04 | Novozymes Biopharma Dk A/S | Albumin variants |
| JP6306700B2 (ja) * | 2013-11-01 | 2018-04-04 | ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ | アルブミン改変体及びその使用 |
| CN107428817B (zh) | 2015-03-12 | 2022-07-12 | 免疫医疗有限责任公司 | 纯化白蛋白融合蛋白的方法 |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| WO2017053617A1 (en) * | 2015-09-23 | 2017-03-30 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| CN108431204A (zh) | 2015-12-22 | 2018-08-21 | 阿尔布梅迪克斯医疗有限公司 | 改良的表达蛋白质的菌株 |
| US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| CA3064037A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
| ES2939461T3 (es) | 2017-11-29 | 2023-04-24 | Csl Ltd | Método para tratar o prevenir la lesión por isquemia-reperfusión |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| SG11202010596PA (en) | 2018-05-16 | 2020-11-27 | Csl Ltd | Soluble complement receptor type 1 variants and uses thereof |
| KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
| US20230220048A1 (en) | 2019-09-06 | 2023-07-13 | Novartis Ag | Therapeutic fusion proteins |
| US20230000774A1 (en) | 2019-12-04 | 2023-01-05 | Albumedix Limited | Methods and compositions produced thereby |
| WO2022166720A1 (zh) * | 2021-02-05 | 2022-08-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
| CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
| EP4608448A1 (en) | 2022-10-28 | 2025-09-03 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| WO2025007195A1 (en) | 2023-07-05 | 2025-01-09 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
| WO2025158071A1 (en) | 2024-01-26 | 2025-07-31 | Sartorius Albumedix Limited | Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction |
| EP4703468A1 (en) | 2024-08-29 | 2026-03-04 | Sartorius Albumedix Limited | Methods and uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404270D0 (en) * | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| EA022201B1 (ru) * | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| CN102458442B (zh) * | 2009-04-08 | 2016-06-29 | 加利福尼亚大学董事会 | 具有受控血清药代动力学的人蛋白支架 |
| CA2789337A1 (en) * | 2010-02-16 | 2011-08-25 | Medimmune, Llc | Hsa-related compositions and methods of use |
-
2011
- 2011-08-09 AU AU2011359378A patent/AU2011359378A1/en not_active Abandoned
- 2011-08-09 WO PCT/US2011/047040 patent/WO2012112188A1/en not_active Ceased
- 2011-08-09 KR KR1020137024189A patent/KR20140012094A/ko not_active Withdrawn
- 2011-08-09 JP JP2013553420A patent/JP2014510518A/ja active Pending
- 2011-08-09 EP EP11858565.2A patent/EP2675471A4/en not_active Withdrawn
- 2011-08-09 CA CA2826683A patent/CA2826683A1/en not_active Abandoned
- 2011-08-09 CN CN2011800674634A patent/CN103379915A/zh active Pending